ATHX-105

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

ATHX-105 is a highly selective serotonin 5-HT 2C receptor agonist which was under development for the treatment of obesity but was never marketed. It is taken orally. The drug has been found to reduce food intake and produce weight loss in animals.

ATHX-105 was developed by Athersys. It reached and completed several phase 1 clinical trials and was preparing to enter phase 2 trials prior to the discontinuation of its development due to safety concerns in March 2009. The chemical structure of ATHX-105 does not appear to have been disclosed.

ATHX-105 is a highly selective serotonin 5-HT 2C receptor agonist which was under development for the treatment of obesity but was never marketed. It is taken orally. The drug has been found to reduce food intake and produce weight loss in animals.

ATHX-105 was developed by Athersys. It reached and completed several phase 1 clinical trials and was preparing to enter phase 2 trials prior to the discontinuation of its development due to safety concerns in March 2009. The chemical structure of ATHX-105 does not appear to have been disclosed.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1335256106 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.